Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 52
2009 44
2010 85
2011 123
2012 171
2013 174
2014 126
2015 154
2016 172
2017 200
2018 186
2019 200
2020 195
2021 161
2022 132
2023 182
2024 199
2025 209
2026 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,492 results

Results by year

Filters applied: . Clear all
Page 1
Publisher's note.
[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):106. doi: 10.1080/13696998.2026.2635859. Epub 2026 Feb 28. J Med Econ. 2026. PMID: 41763986 Free article. No abstract available.
Correction.
[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):431-432. doi: 10.1080/13696998.2026.2632462. Epub 2026 Feb 18. J Med Econ. 2026. PMID: 41708479 Free article. No abstract available.
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.
Dimopoulos MA, Boccadoro M, Einsele H, Rodriguez-Otero P, Hulin C, Perrot A, Leleu X, Caillot D, Facon T, Mina R, Gay F, Broijl A, Hajek R, Spencer A, Schjesvold F, Zweegman S, Nair S, Ammann E, He J, Nobrega M, Rowe M, Sitthi-Amorn A, Sonneveld P. Dimopoulos MA, et al. J Med Econ. 2026 Dec;29(1):421-430. doi: 10.1080/13696998.2026.2624972. Epub 2026 Feb 17. J Med Econ. 2026. PMID: 41701105 Free article. Clinical Trial.
Correction.
[No authors listed] [No authors listed] J Med Econ. 2026 Dec;29(1):249. doi: 10.1080/13696998.2026.2618439. Epub 2026 Jan 21. J Med Econ. 2026. PMID: 41562633 Free article. No abstract available.
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Dranitsaris G, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK, Thompson SL, Teschemaker A, Shetty V, Narkhede M, Ermann D, Blau S. Dranitsaris G, et al. J Med Econ. 2026 Dec;29(1):30-40. doi: 10.1080/13696998.2025.2604971. Epub 2025 Dec 27. J Med Econ. 2026. PMID: 41454883 Free article.
Cost-effectiveness analysis of empagliflozin as an add-on to the standard of care for chronic kidney disease management in the Philippines.
Montilla PJ, Crisostomo AC, Cunanan E, de Lara-Valenzona MR, de Leon D, Encarnacion PJ, Estabillo AP, Gonzales CJ, Mallari-Catungal M, Perlas Tiongco Ii RH, Taneo MJ, Tan-Lim D, Togonon-Leaño JI, Yu D, Kimwell MJ, Villanueva AR. Montilla PJ, et al. J Med Econ. 2026 Dec;29(1):1-15. doi: 10.1080/13696998.2025.2602361. Epub 2025 Dec 24. J Med Econ. 2026. PMID: 41441751 Free article.
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.
Jagannath S, Kharat A, Chinaeke E, Fu AZ, Perciavalle M, Huo S, Qureshi ZP. Jagannath S, et al. J Med Econ. 2025 Dec;28(1):1989-1998. doi: 10.1080/13696998.2025.2583668. Epub 2025 Nov 19. J Med Econ. 2025. PMID: 41178750 Free article.
Addendum.
[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):1682. doi: 10.1080/13696998.2025.2567759. Epub 2025 Sep 29. J Med Econ. 2025. PMID: 41017396 Free article. No abstract available.
Economics of corneal cross-linking for keratoconus treatment.
Rapuano CJ, Lindstrom RL, Donnenfeld E, Berdahl JP, Thompson V, Kratochvil D, Carter J. Rapuano CJ, et al. J Med Econ. 2025 Dec;28(1):1696-1708. doi: 10.1080/13696998.2025.2564576. Epub 2025 Sep 29. J Med Econ. 2025. PMID: 40981503 Free article.
Correction.
[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):1573. doi: 10.1080/13696998.2025.2561429. Epub 2025 Sep 16. J Med Econ. 2025. PMID: 40957609 Free article. No abstract available.
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.
Gordan LN, Fonseca G, Warner A, Alajrash A, Ming A, Tang D, Gavrilov S, Singh N, Heritage T, Griffin E, Swanson A, Slaff S. Gordan LN, et al. J Med Econ. 2025 Dec;28(1):1357-1369. doi: 10.1080/13696998.2025.2548739. Epub 2025 Sep 2. J Med Econ. 2025. PMID: 40891921 Free article.
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy.
Maas L, Contreras-Meca C, Ghezzo S, Belmans F, Corsi A, Cant J, Vos W, Bobowicz M, Rygusik M, Laski DK, Annemans L, Hiligsmann M; EuCanImage Working Group; *EuCanImage Working Group. Maas L, et al. J Med Econ. 2025 Dec;28(1):1023-1036. doi: 10.1080/13696998.2025.2525006. Epub 2025 Jul 11. J Med Econ. 2025. PMID: 40586549 Free PMC article.
Addendum.
[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):986. doi: 10.1080/13696998.2025.2524268. Epub 2025 Jun 24. J Med Econ. 2025. PMID: 40552931 Free article. No abstract available.
Correction.
[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):921. doi: 10.1080/13696998.2025.2520692. Epub 2025 Jun 13. J Med Econ. 2025. PMID: 40512608 Free article. No abstract available.
Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France.
Guilmet C, Lesage H, Cotté FE, Moreau R, Marant Micallef C, Née M, Guitard-Dehoux D, Belhassen M, Danchin N. Guilmet C, et al. J Med Econ. 2025 Dec;28(1):859-870. doi: 10.1080/13696998.2025.2514381. Epub 2025 Jun 6. J Med Econ. 2025. Update in: J Med Econ. 2025 Dec;28(1):986. doi: 10.1080/13696998.2025.2524268. PMID: 40476700 Free article. Updated.
Development and validation of an advanced data analytics model to support strategic point-of-care testing utilization decisions in the emergency department.
Leon-Justel A, Jimenez-Barragan M, Navarro-Bustos C, Martin-Perez S, Garrido-Castilla JM, Morales-Barroso IM, Oltra-Hostalet F, Fernandez-Gallardo MF, Diaz-Luque A, Eugenio-Pizarro A, Luque-Cid A, Sanchez-Mora C. Leon-Justel A, et al. J Med Econ. 2025 Dec;28(1):871-884. doi: 10.1080/13696998.2025.2508659. Epub 2025 Jun 7. J Med Econ. 2025. PMID: 40434437 Free article.
A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop.
Al-Omar HA, Almuhsin AA, Almudaiyan LH, Al-Najjar AH, Abu Esba LC, Almodaimegh H, Altawil ES, Yousef CC, Khan MA, AlYahya K, Alamre J, Maraiki F, Espín J, Tarricone R, Kanavos P. Al-Omar HA, et al. J Med Econ. 2025 Dec;28(1):753-765. doi: 10.1080/13696998.2025.2506967. Epub 2025 May 21. J Med Econ. 2025. PMID: 40371839 Free article.
The benefits of telehealth in promoting equity in blood cancer care - results of a multi-stakeholder forum and systematic literature review.
Mikhael J, Darlington D, Howell B, Hydren J, Hernandez T, Werner S, Iraca T, Arnett M, Gonzalez V, Peschin S, Balch AJ, Moran D, Young-Daniels R, Banjo O, Obeng GD, Asiedu-Ayeh B, Kawuo S, Tukur AM, Mohammed I, Obeng AP, Csanádi M, Lew T, Choon-Quinones M. Mikhael J, et al. J Med Econ. 2025 Dec;28(1):788-802. doi: 10.1080/13696998.2024.2438561. Epub 2025 May 27. J Med Econ. 2025. PMID: 40340653 Free article.
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study.
Ball BJ, Song R, Zanardo E, Huynh L, Mohan M, Pinaire M, Tang D, Yenikomshian M, Swanson A, Gavrilov S, Slaff S. Ball BJ, et al. J Med Econ. 2025 Dec;28(1):719-725. doi: 10.1080/13696998.2025.2498852. Epub 2025 May 21. J Med Econ. 2025. PMID: 40329816 Free article.
Correction.
[No authors listed] [No authors listed] J Med Econ. 2025 Dec;28(1):606. doi: 10.1080/13696998.2025.2494951. Epub 2025 Apr 21. J Med Econ. 2025. PMID: 40259608 Free article. No abstract available.
The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice.
Gnesi M, Daniel F, Mongelli V, Merlo A, Cosentino N, Maurizi AR, Nugnes M, Leogrande M, Degli Esposti L. Gnesi M, et al. J Med Econ. 2025 Dec;28(1):576-585. doi: 10.1080/13696998.2025.2487357. Epub 2025 Apr 17. J Med Econ. 2025. PMID: 40244700 Free article.
2,492 results